Related Experiment Video

Updated: Aug 26, 2025

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.5K

Bioactive compounds modulating Toll-like 4 receptor (TLR4)-mediated inflammation: pathways involved and future

Karen S Coutinho-Wolino1, Patricia P Almeida2, Denise Mafra3

  • 1Postgraduate Program in Cardiovascular Sciences, Fluminense Federal University (UFF), Niterói, RJ, Brazil.

Nutrition Research (New York, N.Y.)
|October 9, 2022
PubMed

Insights

Bioactive compounds from foods may reduce chronic inflammation by targeting Toll-like receptor 4 (TLR4). This review highlights natural compounds that modulate TLR4 pathways, potentially mitigating noncommunicable diseases linked to inflammation.

Area of Science:

  • Biochemistry
  • Immunology
  • Nutrition Science

Background:

  • Chronic inflammation is a key factor in noncommunicable diseases like diabetes, cancer, and cardiovascular disease.
  • Pattern recognition receptors, particularly Toll-like receptor 4 (TLR4), play a critical role in initiating and sustaining inflammatory responses.
  • TLR4 activation triggers multiple inflammatory pathways, increasing the risk and progression of chronic diseases.

Purpose of the Study:

  • To review preclinical evidence on bioactive compounds from natural sources that modulate the TLR4 pathway.
  • To explore the potential of 'food as medicine' strategies for mitigating inflammation via TLR4 antagonism.
  • To identify specific bioactive compounds with anti-inflammatory properties targeting TLR4.

Main Methods:

  • Literature review of preclinical studies on bioactive compounds from fruits, vegetables, spices, and herbs.
  • Analysis of compounds including curcumin, resveratrol, catechin, cinnamaldehyde, emodin, ginsenosides, quercetin, allicin, and caffeine.
  • Examination of mechanisms by which these compounds inhibit TLR4-mediated inflammation.

Main Results:

  • Bioactive compounds demonstrate potential to inhibit TLR4-mediated inflammation through various mechanisms.
  • Mechanisms include modulating gut microbiota, improving intestinal permeability, inhibiting lipopolysaccharide-TLR4 binding, and reducing TLR4 expression.
  • Compounds effectively mitigated inflammation by reducing nuclear factor-κB activation and inflammatory cytokine release.

Conclusions:

  • Bioactive compounds from natural sources show promise in regulating the TLR4 pathway and reducing inflammation.
  • These findings support the concept of nutritional strategies for managing inflammation-mediated diseases.
  • Further clinical studies are warranted to validate the therapeutic potential of these compounds in human diseases.
Keywords:
Bioactive compoundsChronic diseasesInflammationPattern recognition receptorsToll-like receptor 4

More Related Videos

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.6K
A Macrophage Reporter Cell Assay to Examine Toll-Like Receptor-Mediated NF-kB/AP-1 Signaling on Adsorbed Protein Layers on Polymeric Surfaces07:55

A Macrophage Reporter Cell Assay to Examine Toll-Like Receptor-Mediated NF-kB/AP-1 Signaling on Adsorbed Protein Layers on Polymeric Surfaces

Published on: January 7, 2020

7.5K

Related Concept Videos

Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
5.2K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.3K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.8K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.1K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
173
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
215